A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors
Status:
Terminated
Trial end date:
2016-11-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety and tolerability (establish maximum tolerated
dose [MTD], inform the recommended phase 2 dose [RP2D], and identify the dose-limiting
toxicities [DLTs]) of MLN7243.